Meeting
2023 ASCO Annual Meeting
Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group.
Authors
Anna Dorothea Wagner
Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
Anna Dorothea Wagner , Heike I. Grabsch , Murielle Mauer , Uberto Fumagalli Romario , Yoon-Koo Kang , Olivier Bouche , Sylvie Lorenzen , Markus H. Moehler , Peter C. Thuss-Patience , Anneli Elme , Gunnar Folprecht , Uwe Marc Martens , Denis Michel Smith , Maria del Carmen Galan Guzman , Michel Pierre Ducreux , Marc Díez Garcia , Guillaume Piessen , Sun Young Rha , Maike Collienne , Florian Lordick
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT02205047
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4057)
DOI
10.1200/JCO.2023.41.16_suppl.4057
Abstract #
4057
Poster Bd #
378
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INNOVATION trial.
First Author: Anna Dorothea Wagner
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).
First Author: Haeseong Park
Poster
2020 Gastrointestinal Cancers Symposium
KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.
First Author: Hyun Cheol Chung
Poster
2019 ASCO Annual Meeting
KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
First Author: Yelena Yuriy Janjigian